Condition: Pulmonary Hypertension · Interstitial Lung Disease · Sponsor: Liquidia Technologies, Inc.
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Arizona Pulmonary Specialists | Phoenix, Arizona, United States | Recruiting |
| The Medical Research Group, Inc. | Fresno, California, United States | Recruiting |
| University of California San Diego | La Jolla, California, United States | Withdrawn |
| UCLA Westwood | Los Angeles, California, United States | Active Not Recruiting |
| UC Davis | Sacremento, California, United States | Active Not Recruiting |
| UCSF | San Francisco, California, United States | Active Not Recruiting |
| National Jewish Health | Denver, Colorado, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Withdrawn |
| Advent Health | Orlando, Florida, United States | Recruiting |
| Tampa General Hospital Center of Research Excellence | Tampa, Florida, United States | Recruiting |
| Vincent Medical Group | Indianapolis, Indiana, United States | Recruiting |
| Norton Pulmonary Specialists | Louisville, Kentucky, United States | Withdrawn |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06129240